Abstract
Cisplatin is a highly effective antitumor agent whose clinical application is limited by the inherent nephrotoxicity. The current measures of nephroprotection used in patients receiving cisplatin are not satisfactory, and studies have focused on the investigation of new possible protective strategies. Many pathways involved in cisplatin nephrotoxicity have been delineated and proposed as targets for nephroprotection, and many new potentially protective agents have been reported. The multiple pathways which lead to renal damage and renal cell death have points of convergence and share some common modulators. The most frequent event among all the described pathways is the oxidative stress that acts as both a trigger and a result. The most exploited pathways, the proposed protective strategies, the achievements obtained so far as well as conflicting data are summarized and discussed in this review, providing a general view of the knowledge accumulated with past and recent research on this subject.
Similar content being viewed by others
References
Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61–66
Ajith TA, Abhishek G, Roshny D, Sudheesh NP (2009) Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol 61:565–571
Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173–1183
Antunes LM, Darin JD, Bianchi MD (2000) Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 41:405–411
Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464
Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A (2005) Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212:116–123
Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH (2005) Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76:2125–2135
Bae EH, Lee J, Ma SK, Kim IJ, Frokiaer J, Nielsen S, Kim SY, Kim SW (2009) Alpha-lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 24:2692–2700
Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK (2003) Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 142:178–186
Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B (1986) Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 46:5969–5972
Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV (1998) Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int 54:1562–1569
Barnes PJ (1997) Nuclear factor-kappa B. Int J Biochem Cell Biol 29:867–870
Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K (1998) Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J Biol Chem 273:8048–8055
Beehler CJ, Ely ME, Rutledge KS, Simchuk ML, Reiss OK, Shanley PF, Repine JE (1994) Toxic effects of dimethylthiourea in rats. J Lab Clin Med 123:73–80
Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT (2005) Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol 16:452–458
Beyaert R, Fiers W (1994) Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 340:9–16
Block KI, Gyllenhaal C (2005) Commentary: the pharmacological antioxidant amifostine—implications of recent research for integrative cancer care. Integr Cancer Ther 4:329–351
Bonegio R, Lieberthal W (2002) Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 11:301–308
Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ (2002) BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 38:1148–1156
Brouwers EE, Huitema AD, Schellens JH, Beijnen JH (2008) The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anticancer Drugs 19:621–630
Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14:22–34
Burns TF, El-Deiry WS (1999) The p53 pathway and apoptosis. J Cell Physiol 181:231–239
Campbell NP, Kindler HL (2011) Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32:102–110
Campbell MT, Dagher P, Hile KL, Zhang H, Meldrum DR, Rink RC, Meldrum KK (2008) Tumor necrosis factor-alpha induces intrinsic apoptotic signaling during renal obstruction through truncated bid activation. J Urol 180:2694–2700
Candelaria M, Garcia-Arias A, Cetina L, Duenas-Gonzalez A (2006) Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 1:15
Caro AA, Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27–42
Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M (2002) L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55–64
Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167:1477–1484
Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, Park KM, Sheridan AM, Alnemri ES, Bonventre JV, Zervos AS (2005) Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 288:F371–F379
Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93–130
Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:3201S–3204S
Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147–158
Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39:43–50
Cummings BS, McHowat J, Schnellmann RG (2004) Role of an endoplasmic reticulum Ca2+ -independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther 308:921–928
Cvitkovic E (1998) Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24:265–281
Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G (2000a) Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 476:118–123
Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, Kroemer G (2000b) Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 14:729–739
Dillioglugil MO, Maral Kir H, Gulkac MD, Ozon Kanli A, Ozdogan HK, Acar O, Dillioglugil O (2005) Protective effects of increasing vitamin E and a doses on cisplatin-induced oxidative damage to kidney tissue in rats. Urol Int 75:340–344
Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM, Bianchi MdeL (2008) Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 82:363–370
Dong G, Luo J, Kumar V, Dong Z (2009) Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 298:F293–F300
dos Santos OF, Boim MA, Barros EJ, Pirotzky E, Braquet P, Schor N (1991a) Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin. Lipids 26:1324–1328
Dos Santos OF, Boim MA, Barros EJ, Schor N (1991b) Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 40:742–747
Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42
Dumas M, de Gislain C, d’Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N (1990) Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 26:278–282
Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. I. In: Lippert B (ed) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, New York, pp 111–135
El Sabbahy M, Vaidya VS (2011) Ischemic kidney injury and mechanisms of tissue repair. Wiley Interdiscip Rev Syst Biol Med 3:606–618
El-Sayed el SM, Abd-Ellah MF, Attia SM (2008) Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pak J Pharm Sci 21:255–261
Enoksson M, Robertson JD, Gogvadze V, Bu P, Kropotov A, Zhivotovsky B, Orrenius S (2004) Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem 279:49575–49578
Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL (2004) Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66:2202–2213
Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8–15
Francescato HD, Coimbra TM, Costa RS, Bianchi MdeL (2004) Protective effect of quercetin on the evolution of cisplatin-induced acute tubular necrosis. Kidney Blood Press Res 27:148–158
Frick GA, Ballentine R, Driever CW, Kramer WG (1979) Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis. Cancer Treat Rep 63:13–16
Gale GR, Morris CR, Atkins LM, Smith AB (1973) Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 33:813–818
Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW (1990) Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10:353–365
Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171–1176
Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5:260–274
Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32:685–690
Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362–1371
Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657–663
Goossens V, Grooten J, De Vos K, Fiers W (1995) Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92:8115–8119
Gordon JA, Gattone VH 2nd (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991–F998
Guastalla JP, Vermorken JB, Wils JA, George M, Scotto V, Nooij M, ten Bokkel Huinnink WW, Dalesio O, Renard J (1994) Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy–a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer 30A:45–49
Han X, Yue J, Chesney RW (2009) Functional TauT protects against acute kidney injury. J Am Soc Nephrol 20:1323–1332
Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47–61
Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK (1994) Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925–5929
Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW (2001) Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159:1889–1894
Hanigan MH, Deng M, Zhang L, Taylor PT Jr, Lapus MG (2005) Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 288:F125–F132
Hannemann J, Duwe J, Baumann K (1991) Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother Pharmacol 28:427–433
Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584–599
Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR (2010) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol 65:941–951
Hausheer FH, Ding D, Shanmugarajah D, Leverett BD, Huang Q, Chen X, Kochat H, Ayala PY, Petluru PN, Parker AR (2011a) Accumulation of BNP7787 in human renal proximal tubule cells. J Pharm Sci 100:3977–3984
Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, Chen X, Ayala PY, Shanmugarajah D, Kochat H (2011b) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer Chemother Pharmacol 67:381–391
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381
Heidemann HT, Muller S, Mertins L, Stepan G, Hoffmann K, Ohnhaus EE (1989) Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol 97:313–318
Heinecke JW, Kawamura M, Suzuki L, Chait A (1993) Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 34:2051–2061
Helm CW, States JC (2009) Enhancing the efficacy of cisplatin in ovarian cancer treatment—could arsenic have a role. J Ovarian Res 2:2
Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H (1990) Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 45:536–539
Hye Khan MA, Abdul Sattar M, Abdullah NA, Johns EJ (2007) Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol 59:253–260
Iguchi T, Nishikawa M, Chang B, Muroya O, Sato EF, Nakatani T, Inoue M (2004) Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney. Free Radic Res 38:333–341
Ikeda S, Fukuzaki A, Kaneto H, Ishidoya S, Orikasa S (1999) Role of protein kinase C in cisplatin nephrotoxicity. Int J Urol 6:245–250
Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298–14302
Ismaili N, Amzerin M, Elmajjaoui S, Droz JP, Flechon A, Errihani H (2011a) The role of chemotherapy in the management of bladder cancer. Prog Urol 21:369–382
Ismaili N, Amzerin M, Flechon A (2011b) Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 4:35
Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101:41–44
Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467–2498
Jia Z, Wang N, Aoyagi T, Wang H, Liu H, Yang T (2011) Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int 79:77–88
Jiang M, Dong Z (2008) Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 327:300–307
Jiang M, Yi X, Hsu S, Wang CY, Dong Z (2004) Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287:F1140–F1147
Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z (2006) Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25:4056–4066
Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z (2007) Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73:1499–1510
Johnson AL, Ratajczak C, Haugen MJ, Liu HK, Woods DC (2007) Tumor necrosis factor-related apoptosis inducing ligand expression and activity in hen granulosa cells. Reproduction 133:609–616
Jones MM, Basinger MA, Field L, Holscher MA (1991) Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res 11:1939–1942
Kachadourian R, Leitner HM, Day BJ (2007) Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. Int J Oncol 31:161–168
Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y (2004) The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 23:29–34
Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N, Sai Y, Miyamoto K (2010) Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33:1867–1871
Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, Reynolds M, Pappo A, London WB, Malogolowkin M (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–5835
Kaushal GP, Kaushal V, Hong X, Shah SV (2001) Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726–1736
Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112
Khan AH, Sattar MA, Abdullah NA, Johns EJ (2007) Influence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur J Pharmacol 569:110–118
Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19–38
Koyner JL, Sher Ali R, Murray PT (2008) Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol 109:e109–e117
Kruidering M, Maasdam DH, Prins FA, de Heer E, Mulder GJ, Nagelkerke JF (1994) Evaluation of nephrotoxicity in vitro using a suspension of highly purified porcine proximal tubular cells and characterization of the cells in primary culture. Exp Nephrol 2:324–344
Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638–649
Kuhar M, Sen S, Singh N (2006) Role of mitochondria in quercetin-enhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells. Anticancer Res 26:1297–1303
Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480
Lau AH (1999) Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 56:1295–1298
Laughton MJ, Halliwell B, Evans PJ, Hoult JR (1989) Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem Pharmacol 38:2859–2865
Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903–909
Lee RH, Song JM, Park MY, Kang SK, Kim YK, Jung JS (2001) Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol 62:1013–1023
Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK (2006) Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096–2105
Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393–1399
Li G, Sha SH, Zotova E, Arezzo J, Van de Water T, Schacht J (2002) Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82:585–596
Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V (2010) Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides 31:592–602
Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V (2011) Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure. J Mol Neurosci 43:58–66
Lieberthal W, Triaca V, Levine J (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270:F700–F708
Lieberthal W, Menza SA, Levine JS (1998) Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 274:F315–F327
Lin X, Okuda T, Holzer A, Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154–1159
Liu H, Baliga R (2003) Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63:1687–1696
Liu H, Baliga R (2005) Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol 16:1985–1992
Liu H, Baliga M, Baliga R (2002) Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res 22:863–868
Lopez-Novoa JM (1999) Potential role of platelet activating factor in acute renal failure. Kidney Int 55:1672–1682
Losonczy G, Mathe C, Muller V, Szondy K, Moldvay J (2010) Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer. Magy Onkol 54:289–296
Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66:196–202
Luke DR, Vadiei K, Lopez-Berestein G (1992) Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7:1–7
Lynch ED, Gu R, Pierce C, Kil J (2005) Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201:81–89
Masereeuw R, Terlouw SA, van Aubel RA, Russel FG, Miller DS (2000) Endothelin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol Pharmacol 57:59–67
Matsushima H, Yonemura K, Ohishi K, Hishida A (1998) The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 131:518–526
Milner LS, Wei SH, Houser MT (1993) Enhancement of renal and hepatic glutathione metabolism by dimethylthiourea. Toxicol Lett 66:117–123
Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R (2006) Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med 40:1564–1577
Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98–103
Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, Worthen GS (1999) Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest 103:851–858
Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23:2797–2808
Old LJ (1988) Tumor necrosis factor. Sci Am 258(59–60):69–75
Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC (1997) Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 391:79–86
Ormstad K, Uehara N (1982) Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 150:354–358
Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, Yildirim Z (2004) Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 24:27–35
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007
Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505–F511
Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO, Dong Z (2011) Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121:2709–2722
Park MS, De Leon M, Devarajan P (2002) Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13:858–865
Petrosillo G, Ruggiero FM, Paradies G (2003) Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 17:2202–2208
Peyrou M, Hanna PE, Cribb AE (2007) Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 99:346–353
Pirotzky E, Guilmard C, Sidoti C, Ivanow F, Principe P, Braquet P (1990) Platelet-activating factor antagonist, BN-52021 protects against cis-diamminedichloroplatinum nephrotoxicity in the rat. Ren Fail 12:171–176
Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842
Ramesh G, Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610–F618
Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166–F174
Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368–379
Rjiba-Touati K, Ayed-Boussema I, Bouaziz C, Belarbia A, Azzabi A, Achour A, Hassen W, Bacha H (2012) Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug Chem Toxicol 35:89–95
Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC (2010) Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 10:46–53
Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC (2011) Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 189:45–51
Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303–2306
Rosenberg B, Vancamp L, Krigas T (1965) Inhibition of cell division in Escherichia Coli by electrolysis products from a platinum electrode. Nature 205:698–699
Rosenberg B, Renshaw E, Vancamp L, Hartwick J, Drobnik J (1967) Platinum-induced filamentous growth in Escherichia coli. J Bacteriol 93:716–721
Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386
Sadzuka Y, Shoji T, Takino Y (1992) Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett 62:293–300
Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM (2009) Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 55:399–406
Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI (2011a) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 41:803–821
Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM (2011b) Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant 26:3484–3495
Santos NA (2012) Oxidants and inhibition of cisplatin-induced kidney injury: role of mitochondria. In: Spitz DR (ed) Oxidative Stress in Cancer Biology and Therapy, 1st edn. Springer, New York, pp 407–425
Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC (2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81:495–504
Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC (2008) Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61:145–155
Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18
Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441–445
Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, Sasaki T, Makino H (2003) A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 305:1183–1190
Schenellmann RG (2001) Toxic responses of the kidney. In: Kalassen CD (ed) Casarett and Doull’s toxicology. The basic science of poisons, 6th edn. McGraw-Hill, New York, pp 491–514
Schmalhausen EV, Zhlobek EB, Shalova IN, Firuzi O, Saso L, Muronetz VI (2007) Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3-phosphate dehydrogenase. Food Chem Toxicol 45:1988–1993
Schrier RW, Chen YC, Cadnapaphornchai MA (2004) From finch to fish to man: role of aquaporins in body fluid and brain water regulation. Neuroscience 129:897–904
Sergediene E, Jonsson K, Szymusiak H, Tyrakowska B, Rietjens IM, Cenas N (1999) Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett 462:392–396
Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP (2008) Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 13:11–32
Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP (2005) p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280:31230–31239
Sharma H, Sen S, Singh N (2005) Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4:949–955
Sharp PA (2003) Ctr1 and its role in body copper homeostasis. Int J Biochem Cell Biol 35:288–291
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821
Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60:2823–2828
Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M, Rybak LP (2000) Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 86:234–241
Strasser A, O’Connor L, Dixit VM (2000) Apoptosis signaling. Annu Rev Biochem 69:217–245
Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565–573
Tanihara Y, Masuda S, Katsura T, Inui K (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263–1271
Tarladacalisir YT, Kanter M, Uygun M (2008) Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Ren Fail 30:1–8
Tirosh O, Katzhendler Y, Barenholz Y, Ginsburg I, Kohen R (1996) Antioxidant properties of amidothionophosphates: novel antioxidant molecules. Free Radic Biol Med 20:421–432
Togna GI, Togna AR, Franconi M, Caprino L (2000) Cisplatin triggers platelet activation. Thromb Res 99:503–509
Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142–148
Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1–10
Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ (1992) Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013–1019
Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72–82
Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552:335–344
Ueda N, Kaushal GP, Shah SV (2000) Apoptotic mechanisms in acute renal failure. Am J Med 108:403–415
Vondalova Blanarova O, Jelinkova I, Szoor A, Skender B, Soucek K, Horvath V, Vaculova A, Andera L, Sova P, Szollosi J, Hofmanova J, Vereb G, Kozubik A (2011) Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis 32:42–51
Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM (2008) Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 249:184–193
Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628–8633
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320
Ward JP (1975) Gamma-glutamyl transpeptidase. A sensitive indicator of renal ischaemic injury in experimental animals and renal homograft rejection in man. Ann R Coll Surg Engl 57:248–261
Wei Q, Dong G, Franklin J, Dong Z (2007a) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72:53–62
Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z (2007b) Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293:F1282–F1291
Werner M, Costa MJ, Mitchell LG, Nayar R (1995) Nephrotoxicity of xenobiotics. Clin Chim Acta 237:107–154
Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490–F496
Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451–2466
Wu XX, Kakehi Y (2009) Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 15:2039–2047
Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424–431
Yamakawa T, Eguchi S, Matsumoto T, Yamakawa Y, Numaguchi K, Miyata I, Reynolds CM, Motley ED, Inagami T (1999) Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-kappaB and p38 mitogen-activated protein kinase on tumor necrosis factor-alpha production. Endocrinology 140:3562–3572
Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12:5817–5825
Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP (2008) Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 15:530–544
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124
Yee MS, Blakley BW, Begleiter A, Leith M (2008) Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37:638–641
Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K (2005) Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70:1823–1831
Zhang L, Hanigan MH (2003) Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988–994
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
dos Santos, N.A.G., Carvalho Rodrigues, M.A., Martins, N.M. et al. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86, 1233–1250 (2012). https://doi.org/10.1007/s00204-012-0821-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-012-0821-7